Predicting drug resistance

Nicole S Arellano; Shannon E Elf

doi:10.7554/eLife.103775

Predicting drug resistance

Elife. 2024 Nov 6:13:e103775. doi: 10.7554/eLife.103775.

Authors

Nicole S Arellano¹, Shannon E Elf¹

Affiliation

¹ Department of Internal Medicine and the Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, United States.

Abstract

A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.

Keywords: CD26; CD35; CITE-Seq; CML; cancer; cancer biology; genetics; genomics; human; leukemic stem cell.

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Drug Resistance, Neoplasm*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Neoplastic Stem Cells / drug effects

Substances

Antineoplastic Agents